ArticleHealth economics2019
The marginal benefits of healthcare spending in the Netherlands: Estimating cost-effectiveness thresholds using a translog production function.
Article in Health economics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Healthcare Utilization, Costs, and Cost-Effectiveness of Patients Undergoing Laparoscopic and Open Hemihepatectomy: A Secondary Analysis of the ORANGE II PLUS Randomized Controlled, Phase 3, Superiority Trial.Annals of surgical oncology · 2026Trial
- The Efficiency of the German Healthcare System: Some Puzzling Findings.The International journal of health planning and management · 2026Article
- Cost-effectiveness analysis of surgical and non-surgical weight loss interventions in end-stage knee osteoarthritis and obesity: a Markov State model.BMC public health · 2025Article
- Association of Health and Social Spending With Health Outcomes in OECD Countries.Health services research · 2025Article
- Income-related disparities in the value of health care in South Korea.Health affairs scholar · 2025Article
- Health Care Spending Increases and Value in South Korea.JAMA health forum · 2025Article
- Estimating the Incremental Cost Per QALY Produced by the Spanish NHS: A Fixed-Effect Econometric Approach.PharmacoEconomics · 2025Article
- Use of Cost-Effectiveness Thresholds in Healthcare Public Policy: Progress and Challenges.Applied health economics and health policy · 2024Review
- Possibilities and limits of modelling of long-range economic consequences of air pollution - A case study.Heliyon · 2024Article
- A Model-Based Estimate of the Cost-Effectiveness Threshold in Germany.Applied health economics and health policy · 2023Article
- The Broader Opportunity Costs in the Broader Cost-Effectiveness Analysis Framework.Applied health economics and health policy · 2023Article
- Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence-Based Policy.Applied health economics and health policy · 2022Review
- Accounting for country- and time-specific values in the economic evaluation of health-related projects relevant to low- and middle-income countries.Health policy and planning · 2022Article
- Production function for modeling hospital activities. The case of Polish county hospitals.PloS one · 2022Article
- Closed for business: The mortality impact of business closures during the Covid-19 pandemic.PloS one · 2021Article
- Informing a Cost-Effectiveness Threshold for Health Technology Assessment in China: A Marginal Productivity Approach.PharmacoEconomics · 2020Article
- Nonparametric estimation of a primary care production function in urban Brazil.Health economics review · 2020Article
- Assessing the value of human papillomavirus vaccination in Gavi-eligible low-income and middle-income countries.BMJ global health · 2020Article
- Are quality-adjusted medical prices declining for chronic disease? Evidence from diabetes care in four health systems.The European journal of health economics : HEPAC : health economics in prevention and care · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
New technologies may displace existing, higher-value care under a fixed budget. Countries aim to curtail adoption of low-value technologies, for example, by installing cost-effectiveness thresholds. Our objective is to estimate the opportunity cost of hospital care to identify a threshold value for the Netherlands. To this aim, we combine claims data, mortality data and quality of life questionnaires from 2012 to 2014 for 11,000 patient groups to obtain quality-adjusted life-year (QALY) outcomes and spending. Using a fixed effects translog model, we estimate that a 1% increase in hospital spending on average increases QALY outcomes by 0.2%. This implies a threshold of €73,600 per QALY, with 95% confidence intervals ranging from €53,000 to €94,000 per QALY. The results stipulate that new technologies with incremental cost effectiveness ratios exceeding the Dutch upper reference value of €80,000 may indeed displace more valuable care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.